STAT — No opioids, please: A growing movement lets patients refuse prescriptions
The ease of relapsing into opioid addiction has led a growing number of states to help residents make it clear to medical professionals they do not want to be prescribed the powerful painkillers.
The New York Times — G.O.P.’s health care tightrope winds through the blue-collar Midwest
As Republicans in Washington grapple with how to meet their promise of undoing the greatest expansion of health care coverage since the Great Society, they are struggling with what may be an irreconcilable problem: bridging the vast gulf between the expectations of blue-collar voters who propelled Mr. Trump to the presidency, and longstanding party orthodoxy that it is not the federal government’s role to provide benefits to a wide swath of society.
NBC News — U.S. military MDs not prepared to care for transgender patients
While the majority of U.S. military doctors surveyed at a meeting last year felt they could provide “nonjudgmental” care to people who are transgender, most said they have received little or no training on transgender care. Nearly 90 percent of the doctors said they had not received enough training to prescribe hormones to help patients prepare for a gender transition.
The Washington Post —An architect of the ACA is now advising Trump as GOP works to level the law
When bioethicist and oncologist Ezekiel Emanuel meets with President Trump at the White House on Monday, the session will reveal publicly what has been happening privately for months: A trusted ally of former president Barack Obama and chief architect of the Affordable Care Act is trying to help steer how Republicans rework it.
Kaiser Health News — Prescription drug costs are on the rise; so are the TV ads promoting them
“Pharmaceutical advertising has grown more in the past four years than any other leading ad category,” said Jon Swallen, chief research officer at Kantar Media, a consulting firm that tracks multimedia advertising. It exceeded $6 billion last year, with television picking up the lion’s share, according to Kantar data. But the proliferation of drug advertisements has generated new controversy, in part because the ads inevitably promote high-priced drugs, some of which doctors say have limited practical utility for the average patient-viewer.